Jul 7, 2025 08:01AM Allarity Therapeutics (ALLR) names Jeff Ervin as CFO

Jun 30, 2025 08:03AM Allarity Therapeutics (ALLR) Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

Jun 11, 2025 04:07PM Allarity Therapeutics (ALLR) names Jesper Høiland to Board

Jun 4, 2025 08:04AM Allarity Therapeutics (ALLR) Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Actio

May 9, 2025 05:03PM Allarity Therapeutics, Inc. (ALLR) Tops Q1 EPS by 763c

Apr 25, 2025 08:01AM Allarity Therapeutics (ALLR) Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

Mar 24, 2025 08:01AM Allarity Therapeutics (ALLR) Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Mar 17, 2025 08:00AM Allarity Therapeutics (ALLR) Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients

Mar 13, 2025 08:33AM Allarity Therapeutics (ALLR) Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 3, 2025 08:01AM Allarity Therapeutics (ALLR) Announces Board Authorization of $5 Million Share Repurchase Program

Feb 6, 2025 08:01AM Allarity Therapeutics (ALLR) Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Feb 4, 2025 10:51AM Kuehn Law Encourages Investors of Allarity Therapeutics, Inc. to Contact Law Firm

Jan 30, 2025 08:06AM Allarity Therapeutics (ALLR) Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Nov 18, 2024 08:03AM Allarity Therapeutics (ALLR) Reports Key Progress in Phase 2 Stenoparib Trial

Oct 22, 2024 08:00AM Allarity Therapeutics (ALLR) to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

Oct 10, 2024 08:00AM Allarity Therapeutics (ALLR) Regains Compliance with NASDAQ Minimum Bid Price Requirement

Sep 16, 2024 08:00AM Allarity Therapeutics (ALLR) Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

Sep 13, 2024 08:46AM Allarity Therapeutics (ALLR) Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 11, 2024 08:00AM Allarity Therapeutics (ALLR) Announces 1:30 Reverse Share Split

Aug 30, 2024 04:08PM Allarity Therapeutics (ALLR) Files for 18.53M Share Offering by Selling Stockholders

Jul 24, 2024 06:02AM Allarity Therapeutics (ALLR) Encourages Shareholders to Vote FOR the Reverse Stock Split

Jul 22, 2024 06:32AM Allarity Therapeutics (ALLR) Outlines Company’s 2024 Progress and Objectives

Jun 27, 2024 08:01AM Allarity Therapeutics (ALLR) Granted Hearing to Regain Nasdaq Compliance